MRC recognizes the following companies as the key players in the global dengue vaccine market: GlaxoSmithKline, Merck Sharp &Dohme, Sanofi, and Takeda Pharmaceuticals.
Other Prominent Vendors in the market are: GeneOne Life Sciences, Medigen Biologics, Panacea Biotec, and Sun Pharmaceutical.
Commenting on the report, an analyst from MRC’s team said: “One trend in the market is licensing deals. Companies are increasingly focused on developing novel and effective dengue vaccines. Toward that effort, they are engaging in partnerships and collaborations with other market players. Several licensing deals have taken place in the global dengue vaccine market.”
According to the report, one driver in the market is rapid growth in disease prevalence. The prevalence of dengue is rising rapidly. The factors contributing to the rise in dengue cases include an increase in population density and global warming. As per the NIH, 3.6 billion people that reside in tropical and subtropical regions are at risk of dengue transmission. Global estimates vary, but nearly 0.05 to 0.2 billion cases of dengue infections are reported annually. In 2011, annual cases of severe dengue were around 0.5 million, and mortality due to dengue was above 20,000 as per the NIH. As per the NIH, in 2012, the upper bound total was 3.97 billion for people at risk of dengue in 128 countries globally.
Get sample copy of this report @ https://marketreportscenter.com/reports/565044/global-dengue-vaccine-market-2017-2021#
Further, the report states that one challenge in the market is regulatory hurdles in vaccine penetration. Vendors are facing difficulty in getting approvals for the launch of vaccines in several dengue-endemic countries due to the nature of dengue serotypes in different countries. The circulation of dengue serotypes fluctuates in dengue-endemic regions. Hence, vaccine efficacy must be exhibited against all four serotypes for which region-specific clinical trials are required to be conducted. For the inclusion of vaccines in the public immunization program of any country, demographic efficacy and safety data are required, which require additional clinical trials at regional levels at times to comply with the regulatory requirements. This leads to delay in the launch of the product, and ultimately the potential sales get affected negatively.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Check Discount on Report @ https://marketreportscenter.com/request-discount/565044
About Market Reports Center;
Market Reports Center is an e-commerce platform obliging the needs of knowledge workers, experts, professionals who are subject to market research information for their work, or to make strategic business decisions. We are dedicated to create a comprehensive offering of market research which is accurate, credible and affordable.
Market Reports Center currently has more than 4,00,000 plus titles and 50+ Publishers on our platform and growing consistently. We cover more than 35 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Construction, Agriculture, Food, Beverages, Banking & Finance, Media and Government, Public Sector Studies.
Connect for more details:
Sam Collins
Market Reports Center
1-646-883-3044 (US)
Email: info@marketreportscenter.com
Website: https://marketreportscenter.com
No comments:
Post a Comment